GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Clarus Therapeutics Holdings Inc (OTCPK:CRXTQ) » Definitions » Net Change in Cash

Clarus Therapeutics Holdings (Clarus Therapeutics Holdings) Net Change in Cash : $8.90 Mil (TTM As of Jun. 2022)


View and export this data going back to 2021. Start your Free Trial

What is Clarus Therapeutics Holdings Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Clarus Therapeutics Holdings's Net Change in Cash for the three months ended in Jun. 2022 was $10.04 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Jun. 2022 was $8.90 Mil.

Clarus Therapeutics Holdings Net Change in Cash Historical Data

The historical data trend for Clarus Therapeutics Holdings's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clarus Therapeutics Holdings Net Change in Cash Chart

Clarus Therapeutics Holdings Annual Data
Trend Dec20 Dec21
Net Change in Cash
5.58 19.18

Clarus Therapeutics Holdings Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Net Change in Cash Get a 7-Day Free Trial 2.91 11.68 4.46 -17.28 10.04

Clarus Therapeutics Holdings Net Change in Cash Calculation

Clarus Therapeutics Holdings's Net Change in Cash for the fiscal year that ended in Dec. 2021 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-43.786+-0.025+62.993+0
=19.18

Clarus Therapeutics Holdings's Net Change in Cash for the quarter that ended in Jun. 2022

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-17.501+0+27.537+0
=10.04

Net Change in Cash for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $8.90 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clarus Therapeutics Holdings Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Clarus Therapeutics Holdings's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Clarus Therapeutics Holdings (Clarus Therapeutics Holdings) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Clarus Therapeutics Holdings Inc (OTCPK:CRXTQ) » Definitions » Net Change in Cash
Comparable Companies
JMAC KYCH OOGI SMAP ADRT BYNO MEPW TUGC GIAC ARIZ JNJ PFE XSWX:ROG LLY ABBV MRK LSE:AZN XSWX:NOVN BMY XPAR:SAN
Traded in Other Exchanges
N/A
Address
555 Skokie Boulevard, Suite 340, Northbrook, IL, USA, 60062
Website
https://www.clarustherapeutics.com
Clarus Therapeutics Holdings Inc is a pharmaceutical company with expertise in developing androgen and metabolic therapies for men and women, including potential therapies for orphan indications. The company is focused on focused on the commercialization of JATENZO (testosterone undecanoate), the first and only oral testosterone replacement, or testosterone replacement therapy, and JATENZO is the sole source of company's revenue.
Executives
Thomas Mcnerney & Partners Lp 10 percent owner 45 S. 7TH ST., SUITE 3060, MINNEAPOLIS MN 55402
Kimberly M Murphy director 101 EAST KENNEDY BLVD., SUITE 2800, TAMPA FL 33602
Elizabeth Cermak director 1414 RALEIGH ROAD, SUITE 400, CHAPEL HILL NC 27517
Prygocki Mark A Sr director C/O MEDICS, 8125 N. HAYDEN RD, SCOTTSDALE AZ 85258
John Kenneth Amory director C/O CLARUS THERAPEUTICS HOLDINGS, INC., 555 SKOKIE BLVD, SUITE 340, NORTHBROOK IL 60662
Robert E. Dudley director, officer: Chief Executive Officer 555 SKOKIE BOULEVARD, SUITE 340, NORTHBROOK IL 60062
Joseph Hernandez director C/O MICROLIN BIO, INC., NEW YORK NY 10022
Richard D Peterson officer: Chief Financial Officer 1110 WEST COMMERCIAL BOULEVARD, FORT LAUDERDALE FL 33309
Frank Jaeger officer: Chief Commercial Officer CLARUS THERAPEUTICS HOLDINGS, INC., 555 SKOKIE BLVD, SUITE 340, NORTHBROOK IL 60662
Steven A. Bourne officer: Chief Administrative Officer 555 SKOKIE BOULEVARD, SUITE 340, NORTHBROOK IL 60062
Ffi Fund Ltd 10 percent owner DMS HOUSE, 20 GENESIS CLOSE, GRAND CAYMAN, GEORGE TOWN E9 KY1-1208
Thomas, Mcnerney & Partners Ii L.p. 10 percent owner 45 SOUTH 7TH STREET, SUITE 3060, Minneapolis MN 55402
Thomas, Mcnerney & Partners Ii, Llc 10 percent owner 45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402
Tmp Nominee Ii, Llc 10 percent owner 45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402
Tmp Associates Ii Lp 10 percent owner 45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402

Clarus Therapeutics Holdings (Clarus Therapeutics Holdings) Headlines

From GuruFocus

Clarus Therapeutics to Report First Quarter 2022 Financial and Operating Results

By GuruFocusNews GuruFocusNews • 06-21-2022

Clarus Therapeutics Announces Notice of Allowance for Patent Claims Covering CLAR-121 (Testosterone + Anastrozole) for Treatment of Androgen-Mediated Autoimmune Inflammatory Mastitis

By GuruFocusNews GuruFocusNews • 06-29-2022

Clarus Therapeutics Announces Notice of Allowance for Patent Claims Covering CLAR-121 (Testosterone + Anastrozole) for Treatment of Androgen-Mediated Autoimmune Inflammatory Mastitis

By GuruFocusNews GuruFocusNews • 05-30-2022

Clarus Therapeutics to Present New Data for JATENZO� (testosterone undecanoate) at the 2022 American Urological Association Annual Meeting

By GuruFocusNews GuruFocusNews • 07-08-2022

Clarus Therapeutics to Present New Data for JATENZO� (testosterone undecanoate) at ENDO 2022, the Endocrine Society's Annual Meeting

By GuruFocusNews GuruFocusNews • 07-09-2022

Clarus Therapeutics to Present New Data for JATENZO� (testosterone undecanoate) at the 2022 American Urological Association Annual Meeting

By GuruFocusNews GuruFocusNews • 06-18-2022

Clarus Therapeutics to Present New Data for JATENZO� (testosterone undecanoate) at ENDO 2022, the Endocrine Society's Annual Meeting

By GuruFocusNews GuruFocusNews • 06-19-2022

Clarus Therapeutics Announces Issuance of Patent Covering JATENZO� (testosterone undecanoate)

By GuruFocusNews GuruFocusNews • 06-07-2022

Clarus Therapeutics Announces Issuance of Patent Covering JATENZO� (testosterone undecanoate)

By GuruFocusNews GuruFocusNews • 06-17-2022

Clarus Therapeutics Announces Issuance of Patent Covering JATENZO� (testosterone undecanoate)

By GuruFocusNews GuruFocusNews • 06-27-2022